Old Web
English
Sign In
Acemap
>
authorDetail
>
Christopher B. Jones
Christopher B. Jones
Janssen Pharmaceutica
Pharmacokinetics
Medicine
Neutropenia
Pharmacology
Cancer
3
Papers
58
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Abstract B20: Pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment: Results from an open-label, multicenter study.
2015
Clinical Cancer Research
Donna Skee
Jan de Jong
Peter Hellemans
Dominique Swerts
Deborah Conover
Christopher B. Jones
Eric Lawitz
Thomas Marbury
W. Smith
Vijay Chauhan
Juhui James Jiao
Juthamas Sukbuntherng
Erik Mannaert
Show All
Source
Cite
Save
Citations (0)
Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors
2006
Clinical Cancer Research
Alain C. Mita
Lisa A. Hammond
Peter L. Bonate
Geoffrey R. Weiss
Heather McCreery
Samira Syed
Mitchell Garrison
Quincy Chu
Johann S. DeBono
Christopher B. Jones
Steve Weitman
Eric K. Rowinsky
Show All
Source
Cite
Save
Citations (55)
A phase i and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies
2004
Investigational New Drugs
Garry Schwartz
Christopher B. Jones
Mitchell Garrison
Amita Patnaik
Chris H. Takimoto
Heather McCreery
Michael Skinner
Anthony W. Tolcher
Eric K. Rowinsky
Show All
Source
Cite
Save
Citations (3)
1